Nonsurgical treatment options in Peyronie’s Disease: 2016 update

Talib, Raidh A.; Ibrahim, Mohammed A.; Cangüven, Önder

doi:10.5152/tud.2016.40799

Cited by 9 publications

(9 citation statements)

References 40 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1] While emerging intralesional treatments such as Clostridium Collagenase are under investigation, surgery still remains as the definitive treatment of stable PD. [2,3] Although the disease was defined three centuries ago, understanding of its aspects like the etiology, pathological mechanisms, its natural course and treatment algorithms are still underdevelopment. The surgery is offered to patients who cannot enter sexual intercourse due to penile deformity, instability or ED with PD onset duration longer than 12 months and , Bahadır Ermeç stable/painless episode longer than 6 months.…”

Section: Introductionmentioning

confidence: 99%

Peyronie`s disease surgery: Surgical outcomes of 268 cases

Kadıoğlu

Salabaş

Özmez

et al. 2018

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: To assess the outcomes of the surgical techniques used in Peyronie's disease (PD) surgery. Material and methods:Two hundred and sixty-eight patients received surgical treatment for PD. Fifty four and 144 patients underwent simple corporoplasties (shortening procedure, SP, group 1) or plaque incision and grafting surgery (lengthening surgery, LP, group 2), respectively, whereas 70 patients with erectile dysfunction underwent penile prosthesis implantation.Results: Penile plication and Nesbit surgeries were performed in 5 (9%) and 42 (78%) patients out of total 54 patients. In the remaining 7 (13%) patients, Nesbit and plication suture combination was required for complete penile straightening. Mean curvature degree was 52.2±12.3 degrees. Follow up time was 36.1±29.4 months. No significant difference was demonstrated between the two groups in the baseline features and co-morbidities except age. In 144 patients who underwent plaque incision and grafting, mean age and PD onset duration were 54.1±9.2 years and 28.2±17.3 months respectively. Mean curvature degree was 58.4±18.9 degrees. Post-operative follow up time of the second group was 51.1±39.6 months. Additional plication suture was used in 48 patients (33%) patients. Degree of curvature improvement was 37.9±19.1 and 52.1±23.5 in SP and LP respectively (p=0.01). The initial anatomic success rates were 90.4% and 87.5% at their early post-operative follow-ups for group 1 and 2 respectively. These rates dropped to 82.7% and 83.6% at the long term follow-up (36 and 51 months) respectively (p=0.9). Although the average follow-up time of LP group was longer than SP group (52.1 mo vs. 37.0 mo), recurrence rates of these two groups were comparable. The combined functional and anatomical success of patients were demonstrated to be 79% and 75% in shortening and grafting surgery. Shortening surgery was not statistically superior to grafting surgery for patients in terms of having erection with or without the aid of PDE-5 inhibitors (94.4% vs. 88.2%, p=0.28). Shortening surgery makes a difference in the long term follow-up for patients who had erections without the aid of p=0.02). Conclusion:Both SP and LP are successful in terms of penile straightening in the short and long-term follow-up. Curvature degree improvement is greater in LP. Patients who undergo LP surgery may suffer from ED in the long-term follow-ups. Greater percentage of patients who underwent LP require PDE-5 inhibitors usage for sexual intercourse. Despite stated shortcomings, combined success (anatomic and functional) is achieved in three out of four patients for both groups. Penile prosthesis implantation should be preferred for patients with ED and penile deformity.

show abstract

Section: Introductionmentioning

confidence: 99%

Peyronie`s disease surgery: Surgical outcomes of 268 cases

Kadıoğlu

Salabaş

Özmez

et al. 2018

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Oral therapies being used today include vitamin E, carnitine, colchicine, potassium aminobenzoate, and phosphodiesterase type 5 inhibitors. However, none of these agents' effectiveness has been fully proven 6 …”

Section: Introductionmentioning

confidence: 99%

“…However, none of these agents' effectiveness has been fully proven. 6 Molecules such as corticosteroids, verapamil, interferon, and collagenase clostridium histolyticum are commonly used in intralesional therapy. 5 Amongst these, collagenase clostridium histolyticum stands out as the most effective agent, and many studies have proven its effectiveness.…”

mentioning

confidence: 99%

Intralesional low‐dose methylprednisolone for the treatment of active phase Peyronie’s disease: A single‐centre, preliminary prospective non‐randomised study

Üre

Özen

2020

Int J Clin Pract

View full text Add to dashboard Cite

Aim There are a few types of drugs that can be used in the active phase of Peyronie's disease. Methylprednisolone is a corticosteroid with a strong anti‐inflammatory effect. In this study, we aimed to evaluate the effect of intralesional low‐dose methylprednisolone treatment on patients in the active phase of Peyronie's disease. Patients and Methods Forty‐eight patients suffering from Peyronie's disease active phase symptoms were included in the study. Methylprednisolone was administered intralesionally for 8 weeks, once per week, at a dose of 40 mg. The injection was applied to the plaques, which causes maximum curvature. Patients were evaluated before and after treatment for plaque size, angle of curvature, and erectile dysfunction according to the International Index of Erectile Function‐5 and Peyronie's Disease Questionnaire. Results The mean age of the patients was 61.1 (43‐78) years. The mean duration of the symptoms was 3.4 (0‐9) months. The average plaque size before treatment was 13.6 mm (7.1‐16.8) and after treatment, this value decreased to 10.8 mm (4.3‐14.6) (P: .025). The average scores of Peyronie's Disease Questionnaire elements; symptom severity, penile pain, and bother/discomfort were 12.3, 19.1, and 6.2, respectively, before the treatment. These scores were decreased to 8.9, 9.6, and 4.4, respectively, after treatment. All subgroups of Peyronie's Disease Questionnaire scores were significantly improved after treatment (P: .001, P < .001, P: .045, respectively). No adverse events were observed during or after treatment. Conclusion In order to recover the symptoms and signs, new and easily accessible drugs are required for use in the acute period of Peyronie's disease. In this context, treatment with intralesional low‐dose methylprednisolone in acute phase Peyronie's Disease is a promising and safe treatment option.

show abstract

“…Oral therapies being used today include vitamin E, carnitine, colchicine, potassium amino benzoate, and phosphodiesterase type 5 inhibitors. However, none of these agents' effectiveness has been fully proven [6].…”

Section: Introductionmentioning

confidence: 99%

Intralesional Low Dose Methylprednisolone for the Treatment of Active Phase Peyronie’s Disease: A Single Center, Preliminary Prospective Non-Randomised Study

Üre

Özen

2020

Preprint

View full text Add to dashboard Cite

Aim There are few types of drugs that can be used in the active phase of Peyronie's disease. Methylprednisolone is a corticosteroid with a strong anti-inflammatory effect. In this study, we aimed to evaluate the effect of intralesional low dose methylprednisolone treatment on patients in the active phase of Peyronie's disease. Patients and Methods Forty-eight patients suffering from Peyronie's disease active phase symptoms were included in the study. Methylprednisolone was administered intralesionally for 8 weeks, once per week, at a dose of 40 mg. The injection was applied into the plaques, which causes maximum curvature. Patients were evaluated before and after treatment for plaque size, angle of curvature, and erectile dysfunction according to the International Index of Erectile Function-5 and Peyronie's Disease Questionnaire. Results The mean age of the patients was 61.1 (43-78) years. Mean duration of the symptoms was 3.4 (0-9) months. The average plaque size before treatment was 13.6 mm (7.1-16.8) and after treatment, this value decreased to 10.8 mm (4.3-14.6) (p:0.025). The average scores of Peyronie's Disease Questionnaire elements; symptom severity, penile pain and bother/discomfort were 12.3, 19.1 and 6.2, respectively before the treatment. These scores were decreased to 8.9, 9.6 and 4.4, respectively after treatment. All subgroups of Peyronie's Disease Questionnaire scores were significantly improved after treatment (p:0.001, p<0.001, p:0.045, respectively).No adverse events were observed during or after treatment. Conclusion In order to recover the symptoms and signs, new and easily accessible drugs are required for use in the acute period of Peyronie's disease. In this context, treatment with intralesional low dose methylprednisolone in acute phase Peyronie's Disease is a promising and safe treatment option.

show abstract

Nonsurgical treatment options in Peyronie’s Disease: 2016 update

Cited by 9 publications

References 40 publications

Peyronie`s disease surgery: Surgical outcomes of 268 cases

Peyronie`s disease surgery: Surgical outcomes of 268 cases

Intralesional low‐dose methylprednisolone for the treatment of active phase Peyronie’s disease: A single‐centre, preliminary prospective non‐randomised study

Intralesional Low Dose Methylprednisolone for the Treatment of Active Phase Peyronie’s Disease: A Single Center, Preliminary Prospective Non-Randomised Study

Contact Info

Product

Resources

About